
    
      Participants are randomized in a ratio of 1:1:1 into 20 µg recombinant hepatitis B vaccine
      group at months 0, 1, and 6 or 20µg recombinant hepatitis B vaccine group at months 0, 1, 2,
      and 6 or 60µg recombinant hepatitis B vaccine group at months 0, 1, 2, and 6. HBsAg and
      anti-HBs will be tested during the study period. Adverse reactions will be recorded after
      vaccination.
    
  